Humana names Dr. Shantanu Nundy chief medical officer
Humana has appointed Dr. Shantanu Nundy as its new chief medical officer. Dr. Nundy replaces Dr. Kate Goodrich, who departed the company late last year. This change comes as Humana plans to overhaul its Medicare business.
Paralel Advisors LLC Invests $5.29 Million in Humana Inc. $HUM
Paralel Advisors LLC recently acquired a new stake of 13,322 shares in Humana Inc. (NYSE:HUM) worth approximately $5.29 million during the second quarter, making it the 23rd biggest position in their holdings. Humana's latest quarterly earnings surpassed expectations, with EPS of $7.61 and revenue of $40.89 billion, showing a 26.2% year-over-year increase. Despite mixed analyst sentiment resulting in a consensus "Hold" rating and a target price of $395.22, institutional investors collectively own 92.38% of the company's stock.
Wealthfront Advisers LLC Takes $3.40 Million Position in Humana Inc. $HUM
Wealthfront Advisers LLC has acquired a new position in Humana Inc. (NYSE:HUM) during the second quarter, purchasing 8,549 shares valued at approximately $3.40 million. This move is part of broader institutional investor activity, with other hedge funds like Wilkerson Advisory Group LLC and Bogart Wealth LLC also increasing their stakes in the insurance provider. Humana's stock currently holds a consensus "Hold" rating from analysts, with a target price of $395.22.
Insurance moves: Sedgwick, ALKEME, ICW Specialty, C3, Humana, Ameritas
This article details recent leadership appointments and platform launches across six insurance and healthcare organizations: Sedgwick, ALKEME, ICW Specialty, C3 Risk & Insurance Services, Humana, and Ameritas. These strategic moves reflect a continued focus on growth infrastructure, financial discipline, and technology-driven solutions as the companies prepare for future expansion. Key highlights include Sedgwick's new role for carrier growth, ALKEME formalizing its executive team after surpassing 100 locations, and Humana appointing a CMO to shape its AI strategy in healthcare.
Humana taps physician executive as new chief medical officer
Humana has appointed Dr. Shantanu Nundy as its new Chief Medical Officer, effective August 31. Nundy, formerly of Accolade, will focus on integrating clinical insights into Humana's products, platforms, and AI strategies. This move comes as Humana aims to improve margins and efficiency after a challenging period, including refreshing its operating model and culling unprofitable plans.
Can Humana's Star Ratings Rebound Unlock MA Earnings Power?
Humana Inc. (HUM) is focusing on improving its Medicare Advantage (MA) Star Ratings to drive earnings growth and achieve a sustainable pretax margin of at least 3% by 2028. Early efforts show promising results in clinical quality and member engagement, with the upcoming October CMS Stars release being a crucial test. A successful rebound could significantly enhance MA plan economics and investor confidence, while peers like UnitedHealth Group (UNH) and Elevance Health (ELV) also prioritize MA quality.
Humana names Shantanu Nundy as chief medical officer
Humana Inc. (NYSE:HUM) has announced the appointment of Shantanu Nundy, M.D., as its new Chief Medical Officer, effective August 31. Dr. Nundy will report to Humana President and CEO Jim Rechtin and will contribute clinical insights to the company's products, platforms, and AI integration. He brings extensive experience from Accolade and Evolent Health, having also advised organizations like the U.S. FDA on digital health and AI.
Humana Names Shantanu Nundy Chief Medical Officer | HUM Stock News
Humana Inc. announced the appointment of Shantanu Nundy, M.D., as its new Chief Medical Officer, effective August 31. Dr. Nundy, a practicing physician and technology leader, will focus on integrating clinical expertise with technology and AI to enhance Humana's products and care delivery. He will report directly to President and CEO Jim Rechtin and serve on the company's Enterprise Leadership Team.
Humana Names Dr. Shantanu Nundy as Chief Medical Officer
Humana Inc. announced that Dr. Shantanu Nundy will join the company as Chief Medical Officer, effective August 31. Dr. Nundy, a practicing physician and technology leader, will focus on integrating clinical excellence, technology, and AI into Humana's products and platforms. He previously served as EVP of Care Delivery and Chief Health Officer at Accolade, leading technology-driven transformations in healthcare.
Tocqueville Asset Management L.P. Buys Shares of 66,567 Humana Inc. $HUM
Tocqueville Asset Management L.P. recently acquired 66,567 shares of Humana Inc. (NYSE:HUM), valued at approximately $26.44 million, during the second quarter. This purchase represents about 0.06% of Humana's stock, as other institutional investors also adjusted their holdings in the insurance provider. Analysts currently rate Humana as a "Hold" with a consensus price target of $395.22, following recent earnings that beat estimates.
First National Bank of Omaha Takes Position in Humana Inc. $HUM
First National Bank of Omaha has acquired 2,766 shares of Humana Inc. (NYSE:HUM) stock, valued at approximately $1.099 million, during the second quarter. This move is part of a broader trend of institutional investors modifying their holdings in Humana, with significant increases from Vanguard Group, BlackRock Inc., and Capital International Investors. Analysts currently have a consensus "Hold" rating on Humana with a target price of $395.22, following various upgrades and price target adjustments.
Deutsche Bank AG Purchases New Stake in Humana Inc. $HUM
Deutsche Bank AG has acquired a new stake in Humana Inc. (NYSE:HUM) during the second quarter, purchasing 411,221 shares valued at approximately $163.345 million. This acquisition makes Deutsche Bank AG an owner of 0.34% of Humana's stock. Other institutional investors have also adjusted their positions in Humana, while analysts have provided varying price targets and ratings, with the stock currently holding an average "Hold" rating.
Danske Bank A S Purchases New Position in Humana Inc. $HUM
Danske Bank A S has acquired a new position in Humana Inc. (NYSE:HUM) during the second quarter, purchasing 61,897 shares valued at approximately $24.59 million. This makes Danske Bank A S the owner of about 0.05% of Humana. Other institutional investors have also adjusted their holdings in Humana, while analysts have provided varied ratings, with a consensus "Hold" and a price target of $395.22.
Why Is Humana (NYSE:HUM) CenterWell Expansion in Focus After Q2?
Humana's second-quarter results highlight the continued expansion of its CenterWell healthcare services, alongside strong performance in its insurance operations, particularly Medicare Advantage. The company, an S&P 500 component, focuses on government-sponsored healthcare programs, with recent developments including significant patient growth in CenterWell Senior Primary Care and an upcoming Medicaid contract expansion in Illinois. This integrated model of insurance and direct healthcare delivery, with an emphasis on value-based care, remains central to Humana's strategy.
UnitedHealth Stock And 2 Dividend Names For Investors Seeking Stability
Amid rising bankruptcy filings and recession warnings, this article identifies three dividend-focused healthcare stocks for investors seeking stability: Abbott Laboratories (ABT), Elevance Health (ELV), and UnitedHealth Group (UNH). These companies offer defensive traits, recurring revenues, and established dividend records, making them potential candidates for portfolios looking for steadier ground in a volatile market. The article details each company's business model, revenue streams, and factors influencing their dividend profiles and financial stability.
Humana Inc. stock outperforms competitors despite losses on the day
Humana Inc. (HUM) stock declined by 1.04% to $378.02 on Wednesday, marking its third consecutive day of losses. Despite this daily dip, the stock's performance outpaced the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average both rise. The article highlights that Humana's stock still outperformed competitors despite its daily losses.
UnitedHealth Stock Looks Reasonable at 18.39X P/E: Should You Buy Now?
UnitedHealth (UNH) is trading at 18.39X forward 12-month earnings, below its five-year median P/E, suggesting a modest discount despite being above the industry average. The company has shown improved medical care ratios and upward earnings estimate revisions, with analysts seeing further upside. However, regulatory scrutiny, potential tax issues, and membership declines pose ongoing risks.
UnitedHealth Stock Looks Reasonable at 18.39X P/E: Should You Buy Now?
UnitedHealth (UNH) stock is trading at 18.39X forward 12-month earnings, below its five-year median but above the industry average, suggesting a premium for its strong market position. The company has seen improved medical costs, upward earnings estimate revisions for 2026 and 2027, and significant capital returns to shareholders. Despite ongoing regulatory scrutiny and potential membership declines, the stock carries a Zacks Rank #2 (Buy) due to its favorable risk-reward profile and solid fundamentals.
290,935 Shares in Humana Inc. $HUM Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new stake of 290,935 shares in Humana Inc. (NYSE:HUM), valued at approximately $115.56 million. Other large institutional investors have also adjusted their holdings in Humana. The stock currently holds a "Hold" consensus rating from analysts with a price target of $395.22, and it recently reported strong Q2 earnings, exceeding revenue and EPS expectations.
Humana Inc. $HUM Shares Sold by Handelsbanken Fonder AB
Handelsbanken Fonder AB reduced its stake in Humana Inc. by 73.6% in the second quarter, selling 9,256 shares and retaining 3,321 shares valued at approximately $1.32 million. Despite this, institutional investors and hedge funds still own 92.38% of Humana's outstanding shares, with several increasing their positions. Humana reported strong quarterly results, beating EPS estimates and seeing a 26.2% revenue increase year-over-year, leading to an average analyst rating of "Hold" with a price target of $395.22.
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti
Fresenius Medical Care stock is trading near its recent NYSE levels, with a closing price of $23.75 on August 14, 2026, and a slight intraday decline to $23.54 by August 17, 2026. This stability coincides with the company's strategic sale of its 4.9% minority stake in Humacyte, executed under a Rule 10b5-1 plan. The capital allocation move and the stock's steady performance provide a clear reference for investors amid broader positive guidance from the parent company, Fresenius SE.
Soon you can buy Medicare Advantage plans at Costco. What you need to know.
Costco Wholesale is expanding its offerings by partnering with nonprofit insurer SCAN Group to sell jointly branded Medicare Advantage and Medicare supplement plans. This move makes Costco the latest consumer brand to venture into offering health insurance options. The new plans will be available alongside Costco's existing wide range of products and services.
4,403,136 Shares in Humana Inc. $HUM Acquired by Pzena Investment Management LLC
Pzena Investment Management LLC has acquired 4,403,136 shares of Humana Inc. (NYSE:HUM), valued at approximately $1.75 billion, making it their second-largest holding. Humana reported stronger-than-expected quarterly earnings with EPS of $7.61 and revenue growth of 26.2% year over year. Despite mixed analyst sentiment, the stock has a consensus "Hold" rating with an average price target of $395.22.
Oppenheimer Asset Management Inc. Makes New $1.43 Million Investment in HCA Healthcare, Inc. $HCA
Oppenheimer Asset Management Inc. has initiated a new position in HCA Healthcare, Inc. by purchasing 3,669 shares valued at approximately $1.43 million during the second quarter. HCA Healthcare reported strong quarterly results with revenue up 8.7% year-over-year to $20.23 billion and earnings exceeding analyst expectations. The company also declared a quarterly dividend of $0.78 per share, and analysts maintain a consensus "Moderate Buy" rating with an average price target of $465.59.
Law firm investigates Humana directors for poss...
Halper Sadeh LLC is investigating whether Humana Inc. officers and directors breached their fiduciary duties to shareholders. The law firm is encouraging long-term Humana stockholders to contact them to discuss potential corporate governance reforms, financial incentives, or other benefits. This investigation aims to enhance company oversight and shareholder value by addressing possible misconduct.
Did Humana Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Humana Inc. (HUM) breached their fiduciary duties to shareholders. Long-term shareholders of Humana are encouraged to contact the firm to discuss potential legal rights and options, including corporate governance reforms or the return of funds to the company. The firm emphasizes that shareholder involvement can enhance transparency, accountability, and ultimately shareholder value.
PRVA|Privia Health Group Inc|Price:22.000|Chg%:+0.240
This article provides a detailed overview of Privia Health Group Inc (PRVA) stock, including its current price, market data, key figures, and financial performance metrics. It also features a "TradingKey Stock Score," analyst ratings with a target price, and a company profile outlining its business model and shareholder information. The stock currently has an overall "Buy" rating from analysts with a significant upside potential.
7,351 Shares in Humana Inc. $HUM Purchased by S&CO Inc.
S&CO Inc. recently acquired 7,351 shares of Humana Inc. (NYSE:HUM) for approximately $2.9 million, contributing to institutional investors owning 92.38% of the company. Despite a consensus "Hold" rating from analysts and an average price target of $395.22, Humana exceeded its latest quarterly earnings and revenue expectations. However, the company faces near-term earnings forecast revisions and plans to exit certain Medicare Advantage markets in 2027, affecting roughly 600,000 members.
Glenmark USA Agrees to USD 15.28 Mn Settlement With Humana Over Generic Drug Antitrust Claims
Glenmark Pharmaceuticals Inc., USA (Glenmark USA) has reached a $15.28 million settlement with Humana Inc. to resolve antitrust litigation concerning alleged price-fixing and anti-competitive conduct related to generic pharmaceutical products. The settlement, which includes interest, was disclosed by Glenmark Pharmaceuticals, though the company denies all allegations and states that the agreement does not constitute an admission of liability. The full settlement amount has already been accounted for in Glenmark's financials and is not expected to significantly impact its financial position.
Humana Stock Gains 1.1% as 600,000-Member Medicare Reset Tests Its 2028 Margin Plan
Humana (NYSE:HUM) shares rose 1.1% last week as the company navigates a significant Medicare Advantage reset, planning to exit approximately 600,000 members while aiming to retain 40% in other offerings. This strategy is designed to achieve a sustainable pre-tax margin of at least 3% by 2028. Despite rising medical costs, Humana reported strong Q2 2026 results with revenue up 26.2% and adjusted EPS up 21.4%, and continues to forecast at least $9.00 adjusted EPS for the full year.
Oppenheimer Asset Management Inc. Makes New $9.05 Million Investment in Humana Inc. $HUM
Oppenheimer Asset Management Inc. has initiated a new $9.05 million investment in Humana Inc. (NYSE:HUM) by purchasing 22,793 shares in the second quarter. This move comes as other institutional investors have also adjusted their stakes in the insurance provider, which recently reported stronger-than-expected earnings for the quarter. Analysts have issued mixed ratings on Humana, with some upgrading forecasts due to strategic partnerships and anticipated profitability, while others express caution regarding near-term earnings volatility and Medicare Advantage membership changes.
Mirae Asset Global Investments Co. Ltd. Acquires 3,726 Shares of Humana Inc. $HUM
Mirae Asset Global Investments Co. Ltd. increased its stake in Humana Inc. by 14.5% during the second quarter, acquiring an additional 3,726 shares and bringing its total holdings to 29,374 shares valued at approximately $11.7 million. Institutional investors now own 92.38% of Humana's shares. Humana recently exceeded quarterly earnings expectations with an adjusted EPS of $7.61 and revenue of $40.89 billion, although its stock trades below its 52-week high.
3,146 Shares in Humana Inc. $HUM Purchased by Retireful LLC
Retireful LLC recently acquired 3,146 shares of Humana Inc. (NYSE:HUM) for approximately $1.25 million, making it a new institutional investor in the company. Humana reported strong quarterly earnings, surpassing analyst expectations with $7.61 EPS and $40.89 billion in revenue, representing a 26.2% year-over-year increase. Despite a consensus "Hold" rating from analysts and potential headwinds from reducing Medicare Advantage enrollment, the company is focused on Medicaid growth and caregiver retention initiatives.
TriaGen Wealth Management LLC Purchases New Stake in Humana Inc. $HUM
TriaGen Wealth Management LLC has acquired a new stake in Humana Inc. (NYSE:HUM) during the second quarter, purchasing 3,039 shares valued at approximately $1,207,000. This comes as other institutional investors have also adjusted their holdings in the insurance provider. The article also details recent analyst ratings for Humana and summarizes key news impacting the company, including positive outlooks on earnings and partnerships, alongside neutral and negative sentiments regarding leadership changes, legal proceedings, and a planned reduction in Medicare Advantage membership.
CPI | Glenmark to Pay $15.3 Million to Settle Humana Antitrust Claims
Glenmark Pharmaceuticals' U.S. unit has agreed to pay $15.3 million to settle antitrust claims brought by Humana Inc., alleging price fixing and market allocation in the generic-drug industry. This settlement resolves three complaints as part of a broader litigation stretching back to 2016, and while Glenmark disputes the allegations, it aims to reduce litigation uncertainty. This agreement is separate from another $29.628 million settlement with state attorneys general, bringing Glenmark's total settlements to roughly $44.9 million as it continues to operate significantly in the U.S. generic-drug market.
Can Humana Improve Caregiver Retention With HealthStream Deal?
Humana's Medicaid plan, Humana Healthy Horizons, is partnering with HealthStream in Indiana to enhance the home-care workforce by offering 1,000 Home Health Aide scholarships and deploying advanced training tools. This initiative aims to combat high caregiver turnover, with early results showing improved retention for participating providers. Other healthcare peers like UnitedHealth Group and Elevance Health are also implementing strategies to address the home-care workforce shortage.
Humana agrees not to reference Teva's Israel ties at US drug trial
Health insurer Humana has agreed not to refer to drugmaker Teva as an Israeli company during an upcoming U.S. drug price-fixing trial. Teva had requested this, arguing that public views on the Gaza war could unfairly prejudice jurors. The agreement highlights the sensitivity of the Israeli-Palestinian conflict in the U.S. legal context.
UnitedHealth Investor Suit Alleges Security, Governance Lapses
A shareholder lawsuit alleges that UnitedHealth Group Inc. board members ignored significant governance and oversight risks for years, leading to billions in investor losses. The amended complaint details how the company handled cybersecurity after acquiring Change Healthcare, which later suffered the largest U.S. healthcare data breach, and also claims UnitedHealth shut down an internal audit program revealing issues in its Medicare billing. These allegations come amid multiple lawsuits against UnitedHealth concerning misleading investors, neglecting cybersecurity, and improperly denying care.
Cedar deploys agentic AI for patient billing, financial experience
Cedar has launched its Kora Platform, an agentic AI system designed to improve patient billing and financial experiences. This platform can manage inbound and outbound calls, texts, and provides detailed reporting, addressing the growing patient responsibility for medical costs. Kora features caller intent recognition, long-term memory for ongoing cases, and has already demonstrated success with high inbound call containment and increased payment attempts.
Equities Analysts Offer Predictions for Humana Q1 Earnings
Zacks Research has increased its Q1 2027 EPS estimate for Humana to $9.04, maintaining a "Hold" rating, with the full-year consensus at $9.09. Several other firms have also raised price targets or upgraded the stock, though MarketBeat's overall consensus remains "Hold" with an average target of $395.22. Humana recently surpassed expectations with $7.61 EPS and $40.89 billion in revenue, a 26.2% year-over-year increase, and institutional investors hold 92.38% of its shares.
Humana (NYSE:HUM) Downgraded by Zacks Research to "Hold"
Zacks Research has downgraded Humana (NYSE:HUM) from "strong buy" to "hold," projecting Q1 2027 earnings of $9.04 per share. This downgrade comes despite Humana exceeding recent quarterly expectations with EPS of $7.61 and revenue of $40.89 billion. Analyst sentiment remains mixed, with a consensus "hold" rating and an average price target of $395.22.
Molina Healthcare (MOH) Surged on Medicaid Clarity and Robust Results
Molina Healthcare (MOH) saw its shares rally after a strong Q1 2026 earnings report, which reassured investors that the worst of its medical cost ratio deterioration was likely over. The company also benefited from increased clarity on Medicaid spending cuts and favorable 2025 risk-adjustment transfer data for managed care companies. Sycamore Mid Cap Value Equity Strategy maintains its positive thesis on MOH, despite its underperformance in Q2 2026.
Humana stock (HUM) climbs 3% as 2027 COLA calculations obscure rising medical-cost shortfall
Humana (HUM) stock rose by 3% despite a preliminary 3.1% Social Security COLA for 2027, as the main concern for the Medicare insurer remains rising healthcare expenses, not retiree payments. The company's Q2 2026 results showed increased revenue and adjusted EPS, but a higher insurance benefit ratio highlights pressure from medical inflation. Analysts generally have a "Moderate Buy" rating, with modest upside, emphasizing medical-cost execution and membership growth as key uncertainties.
Bunge Stock Flat Despite Wheat Rising 3%; Oilseeds Account for 88% of Profit
Bunge stock remained flat despite a 3% rise in wheat prices because its profit is overwhelmingly dependent on oilseed operations, which contributed 88% of its adjusted segment EBIT in the last quarter, while grain merchandising accounted for only 8.4%. The surge in wheat futures was due to a Ukrainian attack disabling two Russian grain terminals. Bunge recently posted strong Q2 results and raised its 2026 EPS outlook, with analysts maintaining a bullish outlook, though risks include persistent shipping disruptions and integration challenges with Viterra.
Medicare Will Spend More Than $13 Billion on the Medicare Advantage Quality Bonus Program in 2026
Medicare's spending on the Medicare Advantage quality bonus program is projected to reach over $13 billion in 2026, a substantial increase from previous years. While most Medicare Advantage enrollees are in plans qualifying for bonuses, the share has recently declined. The program's costs and benefits, particularly for different plan types and insurers, are subject to ongoing debate and analysis, with recent CMS recalculations further impacting spending.
Humana names new Medicaid president
Humana has appointed James "J.P." Holland as its new senior vice president and president of Medicaid. Holland joins the Louisville health insurer from Johns Hopkins Health Plans, bringing his veteran executive experience to lead Humana's Medicaid business.
SRHQ Dividend: 0.65% Yield, $0.33/Share — History & Dates
SRH U.S. Quality GARP ETF (SRHQ) offers a 0.65% dividend yield, paying $0.33 per share annually with a payout ratio of 0.42. The ETF has been consistently paying dividends since 2022, demonstrating a 5-year dividend growth rate of 13.27%. This article provides a complete history of SRHQ's dividend payments, ex-dividend dates, and related metrics.
Richard Pzena Buys LKQ Corp (LKQ) -- Shares Look 38% Undervalued on GF Value
Richard Pzena's firm significantly increased its stake in LKQ Corp (LKQ), purchasing over 9 million shares at $26.33, bringing total holdings to 15.4 million shares. This move suggests Pzena sees LKQ as a value opportunity, especially after a 17.68% year-to-date decline, classifying the stock as "Significantly Undervalued" with a GF Value of $40.00 against a current price of $24.72. The investment aligns with Pzena's strategy of targeting good businesses temporarily priced at a discount, betting on a cyclical recovery for LKQ despite some short-term financial pressures.
Humana taps ex-Johns Hopkins exec as Medicaid leader
Humana has appointed James “J.P.” Holland, formerly president and CEO of Johns Hopkins Health Plans, as its new senior vice president and president of Medicaid. This strategic move, effective August 17, is part of a broader leadership transition and aims to bolster Humana's Medicaid division, a key growth area for the insurer. Holland's extensive experience in government-sponsored programs and managed care is expected to be invaluable as Humana continues to expand its Medicaid business, which currently serves over 1.6 million members in 11 states.
Glenmark settles Humana antitrust lawsuit for $15.28 million
Glenmark Pharmaceuticals has settled antitrust lawsuits with Humana for $15.28 million, resolving claims related to generic drug pricing dating back to 2016. The company stated that the full settlement amount, including interest, has already been provided for in its financial records, indicating no significant immediate impact on its current financial position or earnings per share. Glenmark USA denies any admission of liability or wrongdoing in the settlement, which covers a subset of consolidated lawsuits in the U.S.
